ZA881077B - Macromolecular platinum antitumor compounds - Google Patents
Macromolecular platinum antitumor compoundsInfo
- Publication number
- ZA881077B ZA881077B ZA881077A ZA881077A ZA881077B ZA 881077 B ZA881077 B ZA 881077B ZA 881077 A ZA881077 A ZA 881077A ZA 881077 A ZA881077 A ZA 881077A ZA 881077 B ZA881077 B ZA 881077B
- Authority
- ZA
- South Africa
- Prior art keywords
- antitumor compounds
- platinum antitumor
- macromolecular
- macromolecular platinum
- tumor
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052697 platinum Inorganic materials 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Insulating Materials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/018,715 US4793986A (en) | 1987-02-25 | 1987-02-25 | Macromolecular platinum antitumor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA881077B true ZA881077B (en) | 1988-08-11 |
Family
ID=21789419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA881077A ZA881077B (en) | 1987-02-25 | 1988-02-16 | Macromolecular platinum antitumor compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4793986A (xx) |
| EP (1) | EP0280474B1 (xx) |
| JP (1) | JPS63284134A (xx) |
| AT (1) | ATE96679T1 (xx) |
| AU (1) | AU596774B2 (xx) |
| CA (1) | CA1305665C (xx) |
| DE (1) | DE3885317T2 (xx) |
| DK (1) | DK96588A (xx) |
| IE (1) | IE63003B1 (xx) |
| NO (1) | NO175964C (xx) |
| NZ (1) | NZ223549A (xx) |
| ZA (1) | ZA881077B (xx) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956454A (en) * | 1984-06-27 | 1990-09-11 | Johnson Matthey Plc | Monoclonal antibody - platinum co-ordination compound complex |
| US4952676A (en) * | 1984-06-27 | 1990-08-28 | Johnson Matthey Plc | Monoclonal antibody-platinum co-ordination compound complex |
| GB8806224D0 (en) * | 1988-03-16 | 1988-04-13 | Johnson Matthey Plc | Platinum chemotherapeutic product |
| US5057301A (en) * | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
| US4931553A (en) * | 1988-05-11 | 1990-06-05 | Gill Devinder S | Platinum-polymer complexes and their use as antitumor agents |
| SU1685944A1 (ru) * | 1988-06-06 | 1991-10-23 | Институт Физической Химии Им.Л.В.Писаржевского | Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью |
| US5010176A (en) * | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| US5639624A (en) * | 1989-03-14 | 1997-06-17 | Board Of Regents Of The University Of Nebraska | Monoclonal antibodies specific for metallic cations and method therefor |
| EP0589487A1 (en) * | 1989-03-14 | 1994-03-30 | Board Of Regents Of The University Of Nebraska | Monoclonal antibodies for small organic molecules |
| US5972656A (en) * | 1989-03-14 | 1999-10-26 | Bionebraska, Inc. | Mercury binding polypeptides and nucleotides coding therefore |
| ATE127476T1 (de) * | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
| US6713443B1 (en) * | 1993-10-04 | 2004-03-30 | Institut Pasteur | Compounds which modify serotoninergic transmission, diagnostic and therapeutic applications |
| EP0692252B1 (en) * | 1994-06-14 | 2001-04-04 | "Raffinerie Tirlemontoise", société anonyme: | Use of a composition containing inulin or oligofructose in cancer treatment |
| AU2701395A (en) * | 1994-06-27 | 1996-01-19 | General Hospital Corporation, The | Graft co-polymer adducts of platinum (ii) compounds |
| US5811510A (en) * | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| US6111079A (en) * | 1995-06-05 | 2000-08-29 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefore |
| JP2002508758A (ja) * | 1997-06-12 | 2002-03-19 | エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー | 生物的に活性な材料 |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| WO2001049696A1 (en) * | 2000-01-04 | 2001-07-12 | Access Pharmaceuticals, Inc. | N,o-amidomalonate platinum complexes |
| CA2723664A1 (en) | 2000-03-22 | 2001-09-27 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
| US6455073B1 (en) | 2000-07-10 | 2002-09-24 | Enzrel, Inc. | Covalent microparticle-drug conjugates for biological targeting |
| US20030082102A1 (en) * | 2001-06-25 | 2003-05-01 | Court Wayne S. | Radioactive platinum complexes for cancer treatment |
| US7838619B2 (en) | 2002-01-14 | 2010-11-23 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
| JP4800614B2 (ja) | 2002-07-19 | 2011-10-26 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および使用のための方法 |
| US7138520B2 (en) * | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
| DE602004032553D1 (de) | 2003-09-05 | 2011-06-16 | Gen Hospital Corp | Polyacetal-arzneimittelkonjugate als freisetzungssystem |
| US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| EP1745802A1 (en) * | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| US20090148958A1 (en) * | 2006-04-27 | 2009-06-11 | Onecell Inc. | Nucleotide-transition metal complex catalyst |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US20080300389A1 (en) * | 2007-06-04 | 2008-12-04 | Yang David J | Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| KR20110102420A (ko) | 2008-12-10 | 2011-09-16 | 메르사나 테라퓨틱스, 인코포레이티드 | 생분해성 및 생체적합성 캄토테신-중합체 접합체의 약학 제제 |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| NL2020121B1 (en) * | 2017-12-19 | 2019-06-26 | Linxis B V | Platinum-based functional moieties for preparing cell targeting conjugates |
| NL2020120B1 (en) * | 2017-12-19 | 2019-06-26 | Linxis B V | Methods for preparing cell targeting conjugates and conjugates obtainable by said methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4385046A (en) * | 1980-12-15 | 1983-05-24 | Minnesota Mining And Manufacturing Company | Diagnostic radio-labeled polysaccharide derivatives |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| IL66338A (en) * | 1982-07-15 | 1986-03-31 | Yeda Res & Dev | Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins |
| US4584392A (en) * | 1982-11-10 | 1986-04-22 | Inco Alloys International, Inc. | Platinum and palladium complexes |
| IL67789A (en) * | 1983-01-31 | 1986-09-30 | Yissum Res Dev Co | Amino-substituted malonato platinum(ii)complexes and method for their preparation |
| US4673754A (en) * | 1983-10-14 | 1987-06-16 | Inco Alloys International, Inc. | Platinum and palladium complexes |
| EP0167310B1 (en) * | 1984-06-27 | 1991-05-29 | Johnson Matthey Public Limited Company | Platinum co-ordination compounds |
| IL73972A0 (en) * | 1984-12-31 | 1985-03-31 | Yeda Res & Dev | Agents based on platinum compounds |
-
1987
- 1987-02-25 US US07/018,715 patent/US4793986A/en not_active Expired - Fee Related
-
1988
- 1988-02-16 ZA ZA881077A patent/ZA881077B/xx unknown
- 1988-02-17 NZ NZ223549A patent/NZ223549A/xx unknown
- 1988-02-17 NO NO880705A patent/NO175964C/no unknown
- 1988-02-19 EP EP88301410A patent/EP0280474B1/en not_active Expired - Lifetime
- 1988-02-19 AT AT88301410T patent/ATE96679T1/de active
- 1988-02-19 DE DE88301410T patent/DE3885317T2/de not_active Expired - Fee Related
- 1988-02-24 DK DK096588A patent/DK96588A/da not_active Application Discontinuation
- 1988-02-24 AU AU12135/88A patent/AU596774B2/en not_active Ceased
- 1988-02-24 CA CA000559655A patent/CA1305665C/en not_active Expired - Lifetime
- 1988-02-24 IE IE49888A patent/IE63003B1/en not_active IP Right Cessation
- 1988-02-25 JP JP63043257A patent/JPS63284134A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IE880498L (en) | 1988-08-25 |
| IE63003B1 (en) | 1995-03-08 |
| NO175964C (no) | 1995-01-11 |
| US4793986A (en) | 1988-12-27 |
| CA1305665C (en) | 1992-07-28 |
| AU596774B2 (en) | 1990-05-10 |
| DK96588A (da) | 1988-08-26 |
| DE3885317D1 (de) | 1993-12-09 |
| NO880705L (no) | 1988-08-26 |
| JPS63284134A (ja) | 1988-11-21 |
| AU1213588A (en) | 1988-09-01 |
| DK96588D0 (da) | 1988-02-24 |
| EP0280474B1 (en) | 1993-11-03 |
| EP0280474A2 (en) | 1988-08-31 |
| ATE96679T1 (de) | 1993-11-15 |
| NO175964B (no) | 1994-10-03 |
| EP0280474A3 (en) | 1990-01-31 |
| NO880705D0 (no) | 1988-02-17 |
| NZ223549A (en) | 1989-10-27 |
| DE3885317T2 (de) | 1994-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0280474A3 (en) | Macromolecular platinum antitumor compounds | |
| MX9700553A (es) | Anticuerpos que activan un receptor de eritropoyetina. | |
| IL87885A0 (en) | Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours | |
| EP0275005A3 (en) | Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them | |
| ES8401971A1 (es) | Procedimiento para la preparacion de nuevos 6,11-dihidro-dibenzo-(b,e)-tiepin-11-n-alcohilnorescopin-eteres. | |
| FR2680507B1 (fr) | Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| IN170909B (xx) | ||
| UA29466C2 (uk) | Фармацевтична композиція з антипухлинною активністю | |
| EP0200024A3 (en) | 3-cyano-pyridines, process for their preparation and their pharmaceutical use | |
| PH18031A (en) | Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same | |
| AU1313883A (en) | Perfluorohydrocarbons as vehicles for drugs | |
| JO1406B1 (en) | Chemical compounds | |
| ES483661A1 (es) | Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos | |
| EP0303687A4 (en) | COMPOSITIONS FOR IMPROVING ADCC THERAPIES. | |
| EP0227809A4 (en) | METHOD AND COMPOSITION FOR TREATING CANCER AND NON-MALIGNAL TUMORS. | |
| IL85189A (en) | Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them | |
| ES8406468A1 (es) | Procedimiento para la obtencion de derivados de terc.-butanol sustituidos | |
| KR950700684A (ko) | 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use) | |
| ATE3036T1 (de) | 2-substituierte-4-alkyl bzw trihaloalkyl-5oxazolcarbons[urederivate, deren verwendung als antidote fuer kulturpflanzen und sie enthaltende zusammensetzungen. | |
| ES466257A1 (es) | Un procedimiento para la preparacion de nuevas aralquilani- linas sustituidas | |
| DE3483735D1 (en) | Hexahydropyrrolo(2,1-a)isochinolinderivate. | |
| ES8505351A1 (es) | Un procedimiento para preparar nuevas aroilimidazolonas | |
| SU568574A1 (ru) | Прижимной механизм вертикального двухленточного конвейера | |
| ES8307789A1 (es) | "un procedimiento para la preparacion de derivados de piridina y pirrolidina". | |
| NL190506B (nl) | Werkwijze voor de bereiding van veevoeder of een bestaand deel daarvan door concentreren van de uitgangsstoffen, verlagen van de ph en toevoegen van conserveermiddel. |